• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NuCana plc

    8/20/25 4:20:04 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    6-K
    false2025-06-30Q20001709626--12-31 0001709626 2025-01-01 2025-06-30 0001709626 2024-01-01 2024-06-30 0001709626 2025-04-01 2025-06-30 0001709626 2024-04-01 2024-06-30 0001709626 2024-12-31 0001709626 2025-06-30 0001709626 2025-08-11 2025-08-11 0001709626 2025-04-16 2025-04-16 0001709626 2024-01-01 2024-12-31 0001709626 2025-05-31 2025-05-31 0001709626 2023-12-31 0001709626 2024-06-30 0001709626 ncna:LongTermIncentivePlanMember 2024-01-01 2024-06-30 0001709626 ifrs-full:RetainedEarningsMember 2024-01-01 2024-06-30 0001709626 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-01-01 2024-06-30 0001709626 ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptionsMember 2024-01-01 2024-06-30 0001709626 ifrs-full:ForeignCountriesMember 2024-01-01 2024-06-30 0001709626 ifrs-full:IssuedCapitalMember 2024-01-01 2024-06-30 0001709626 ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001709626 ifrs-full:CountryOfDomicileMember 2024-01-01 2024-06-30 0001709626 ifrs-full:ForeignCountriesMember 2024-04-01 2024-06-30 0001709626 ifrs-full:CountryOfDomicileMember 2024-04-01 2024-06-30 0001709626 ncna:TwoThousandSixteenShareOptionSchemeAndTwentyAndTwentyLongTermIncentivePlanMember 2024-04-01 2024-06-30 0001709626 ncna:LongTermIncentivePlanMember 2025-01-01 2025-06-30 0001709626 ncna:PatentMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025FiveMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateOneMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025FourMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateOneMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025OneMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateTwoMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025TwoMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateTwoMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025OneMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateThreeMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025TwoMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateThreeMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025OneMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateFourMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025TwoMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateFourMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025ThreeMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateOneMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025OneMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateOneMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025TwoMember ncna:TwoThousandTwentyThreeShareOptionsMember ncna:ShareBasedCompensationAwardVestingDateOneMember 2025-01-01 2025-06-30 0001709626 ifrs-full:CountryOfDomicileMember 2025-01-01 2025-06-30 0001709626 ifrs-full:RetainedEarningsMember 2025-01-01 2025-06-30 0001709626 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025ThreeMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025TwoMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025OneMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025FiveMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-01-01 2025-06-30 0001709626 ncna:GrantDateJune202025FourMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-01-01 2025-06-30 0001709626 ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptionsMember 2025-01-01 2025-06-30 0001709626 ifrs-full:ForeignCountriesMember 2025-01-01 2025-06-30 0001709626 ifrs-full:IssuedCapitalMember 2025-01-01 2025-06-30 0001709626 ncna:DeferredShareCapitalMember 2025-01-01 2025-06-30 0001709626 ifrs-full:SharePremiumMember 2025-01-01 2025-06-30 0001709626 ncna:OrdinaryShareCapitalMember 2025-01-01 2025-06-30 0001709626 ncna:DirectorsMember ifrs-full:TopOfRangeMember 2025-01-01 2025-06-30 0001709626 ncna:ConsultantsMember ifrs-full:TopOfRangeMember 2025-01-01 2025-06-30 0001709626 ncna:EmployeesMember ifrs-full:TopOfRangeMember 2025-01-01 2025-06-30 0001709626 ncna:AmericanDepositoryReceiptsMember 2025-01-01 2025-06-30 0001709626 ncna:SeriesAAndSeriesBWarrantsMember 2025-01-01 2025-06-30 0001709626 ifrs-full:ForeignCountriesMember 2025-04-01 2025-06-30 0001709626 ifrs-full:CountryOfDomicileMember 2025-04-01 2025-06-30 0001709626 ncna:TwoThousandSixteenShareOptionSchemeAndTwentyAndTwentyLongTermIncentivePlanMember 2025-04-01 2025-06-30 0001709626 ncna:SeriesBWarrantsMember 2025-04-01 2025-06-30 0001709626 ncna:SeriesAWarrantsMember 2025-04-01 2025-06-30 0001709626 ncna:PatentMember 2025-06-30 0001709626 ifrs-full:OrdinarySharesMember 2025-06-30 0001709626 ifrs-full:ForeignCountriesMember 2025-06-30 0001709626 ncna:GrantDateJune202025ThreeMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-06-30 0001709626 ncna:GrantDateJune202025TwoMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-06-30 0001709626 ncna:GrantDateJune202025FiveMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-06-30 0001709626 ncna:GrantDateJune202025FourMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-06-30 0001709626 ncna:GrantDateJune202025OneMember ncna:TwoThousandTwentyThreeShareOptionsMember 2025-06-30 0001709626 ifrs-full:CountryOfDomicileMember 2025-06-30 0001709626 ncna:DeferredShareCapitalMember 2025-06-30 0001709626 ncna:SeriesAWarrantsMember 2025-06-30 0001709626 ncna:PatentMember 2024-12-31 0001709626 ifrs-full:OrdinarySharesMember 2024-12-31 0001709626 ifrs-full:ForeignCountriesMember 2024-12-31 0001709626 ifrs-full:CountryOfDomicileMember 2024-12-31 0001709626 ncna:DeferredShareCapitalMember 2024-12-31 0001709626 ncna:ATMProgramMember ifrs-full:MajorOrdinaryShareTransactionsMember 2025-07-01 2025-07-31 0001709626 ncna:ATMProgramMember ifrs-full:OrdinarySharesMember ifrs-full:MajorOrdinaryShareTransactionsMember 2025-07-01 2025-07-31 0001709626 ifrs-full:MajorOrdinaryShareTransactionsMember ncna:SeriesAWarrantsMember 2025-07-01 2025-07-31 0001709626 ncna:ATMProgramMember ifrs-full:OrdinarySharesMember ifrs-full:MajorOrdinaryShareTransactionsMember 2025-07-31 0001709626 ifrs-full:OrdinarySharesMember 2025-04-23 0001709626 ifrs-full:OrdinarySharesMember 2025-04-23 2025-04-23 0001709626 ncna:DeferredShareCapitalMember 2025-04-23 2025-04-23 0001709626 ncna:SeriesAWarrantsMember 2025-06-30 2025-06-30 0001709626 ncna:AdsMember 2025-05-31 2025-05-31 0001709626 ncna:PreFundedWarrantMember 2025-05-31 2025-05-31 0001709626 ncna:SeriesBWarrantsMember 2025-05-31 2025-05-31 0001709626 ncna:SeriesBWarrantsMember ifrs-full:TopOfRangeMember 2025-05-31 2025-05-31 0001709626 ncna:SeriesBWarrantsMember ifrs-full:BottomOfRangeMember 2025-05-31 2025-05-31 0001709626 ifrs-full:CapitalReserveMember 2023-12-31 0001709626 ifrs-full:RetainedEarningsMember 2023-12-31 0001709626 ifrs-full:IssuedCapitalMember 2023-12-31 0001709626 ifrs-full:SharePremiumMember 2023-12-31 0001709626 ifrs-full:CapitalRedemptionReserveMember 2023-12-31 0001709626 ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptionsMember 2023-12-31 0001709626 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001709626 ifrs-full:IssuedCapitalMember 2024-06-30 0001709626 ifrs-full:SharePremiumMember 2024-06-30 0001709626 ifrs-full:CapitalRedemptionReserveMember 2024-06-30 0001709626 ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptionsMember 2024-06-30 0001709626 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-06-30 0001709626 ifrs-full:CapitalReserveMember 2024-06-30 0001709626 ifrs-full:RetainedEarningsMember 2024-06-30 0001709626 ifrs-full:IssuedCapitalMember 2024-12-31 0001709626 ifrs-full:SharePremiumMember 2024-12-31 0001709626 ifrs-full:CapitalRedemptionReserveMember 2024-12-31 0001709626 ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptionsMember 2024-12-31 0001709626 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-12-31 0001709626 ifrs-full:CapitalReserveMember 2024-12-31 0001709626 ifrs-full:RetainedEarningsMember 2024-12-31 0001709626 ncna:OrdinaryShareCapitalMember 2024-12-31 0001709626 ncna:DeferredShareCapitalMember 2024-12-31 0001709626 ifrs-full:CapitalReserveMember 2025-06-30 0001709626 ifrs-full:RetainedEarningsMember 2025-06-30 0001709626 ifrs-full:IssuedCapitalMember 2025-06-30 0001709626 ifrs-full:SharePremiumMember 2025-06-30 0001709626 ifrs-full:CapitalRedemptionReserveMember 2025-06-30 0001709626 ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptionsMember 2025-06-30 0001709626 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-06-30 0001709626 ncna:OrdinaryShareCapitalMember 2025-06-30 0001709626 ncna:DeferredShareCapitalMember 2025-06-30 iso4217:GBP xbrli:shares xbrli:pure iso4217:USD iso4217:GBP xbrli:shares ncna:Subsidiary utr:Year ncna:Plan ncna:warrant utr:Y
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM 6-K
     
     
    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO
    RULE 13a-16 OR 15d-16
    OF THE SECURITIES EXCHANGE ACT OF 1934
    For the month of August 2025
    (Commission
    File No. 001-38215)
     
     
    NUCANA PLC
    (Translation of registrant’s name into English)
     
     
    3 Lochside Way
    Edinburgh EH12 9DT
    United Kingdom
    (Address of registrant’s principal executive office)
     
     
    Indicate by check mark whether the registrant files or will file annual reports under
    cover Form 20-F or Form 40-F.
    Form 20-F ☒   Form 40-F ☐
    Indicate by check mark if the registrant is submitting
    the Form 6-K in
    paper as permitted by
    Regulation S-T Rule 101 (b) (1): ☐
    Indicate by check mark if the registrant is submitting
    the Form 6-K in
    paper as permitted by
    Regulation S-T Rule 101 (b) (7): ☐
     
     
     


    Other Events

    On August 20, 2025, NuCana plc (the “Company”) issued a press release announcing its second quarter 2025 financial results. The Company’s unaudited condensed consolidated financial statements as of June 30, 2025 are attached as Exhibit 99.1 and are incorporated by reference herein. The Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations is attached hereto as Exhibit 99.2, and is incorporated by reference herein. The press release is attached as Exhibit 99.3 hereto and is incorporated by reference herein.

    The information in the attached Exhibits 99.1 and 99.2 shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (File Number 333-281576), and Form S-8 (File Number 333-223476 and File Number 333-248135), and related prospectuses, as such registration statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

    The information in the attached Exhibit 99.3 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

    Exhibits

     

    Exhibit

      

    Description

     99.1    Unaudited Condensed Consolidated Financial Statements as of June 30, 2025 and for the Three and Six Months Ended June 30, 2025 and 2024
     99.2    Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Six Months Ended June 30, 2025 and 2024
     99.3    Press Release Dated August 20, 2025
    101.INS    XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
    101.SCH    INLINE XBRL Taxonomy Extension Schema Document
    101.DEF    INLINE XBRL Taxonomy Extension Calculation Linkbase Document
    101.CAL    INLINE XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB    INLINE XBRL Taxonomy Extension Label Linkbase Document
    101.PRE    INLINE XBRL Taxonomy Extension Presentation Linkbase Document
    104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

     

    NuCana plc
    By:   /s/ Ian Webster
    Name:   Ian Webster
    Title:   Interim Chief Financial Officer (Principal Financial and Accounting Officer)

    Date: August 20, 2025

    Get the next $NCNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuCana downgraded by William Blair

    William Blair downgraded NuCana from Outperform to Mkt Perform

    8/30/24 7:44:58 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana downgraded by Cowen & Co.

    Cowen & Co. downgraded NuCana from Outperform to Market Perform

    3/3/22 6:12:40 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on NuCana with a new price target

    HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

    11/24/21 6:13:12 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

    11/1/21 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

    EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

    8/10/21 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NuCana plc

    SC 13G/A - NuCana plc (0001709626) (Subject)

    10/4/24 10:14:46 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NuCana plc (Amendment)

    SC 13D/A - NuCana plc (0001709626) (Subject)

    2/27/24 4:29:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    SC 13G/A - NuCana plc (0001709626) (Subject)

    2/14/24 4:26:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    SEC Filings

    View All

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    8/20/25 4:20:04 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    8/1/25 4:22:05 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    7/21/25 8:15:16 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

    First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development pr

    8/20/25 4:05:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Announces ADS Ratio Change

    EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces that it will implement the Company's previously disclosed plans to change the ratio of its American Depository Shares ("ADSs") to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on August 11, 2025 (the "Effective Date").   For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-two hundred reverse ADS split and will have no impact on an ADS holder's pro

    8/1/25 4:05:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

    EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering. This follows the Company's June 27, 2025 announcement of the agreements to cancel the remaining Series A Warrants, 59.5 million as at June 26, 2025, in exchange for a payment of $3.6 million. This initiative fully eliminates all overhanging rights from the regis

    7/21/25 8:05:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care